Uncovering Hidden Gems: Two Stocks Worth Investing In
When it comes to investing, timing is everything. While some investors shy away from stocks near their 52-week lows, others see it as an opportunity to buy into a company at a discounted price. This approach can be particularly effective when paired with thorough research and a solid understanding of the company’s potential.
Gene Editing Pioneer: CRISPR Therapeutics
CRISPR Therapeutics, a mid-stage biotech company, has been making waves in the gene editing space. With its Nobel Prize-winning CRISPR technique, the company has developed Casgevy, a treatment for rare blood disorders. Although the drug is not yet generating revenue, its potential is vast, with a projected peak sales figure of over $1 billion. Additionally, CRISPR has several promising pipeline candidates, including CTX112, which has received the Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. This designation accelerates the development of therapies and is reserved for investigational medicines that meet certain conditions.
While there are risks associated with CRISPR Therapeutics, its shares could soar if the company makes progress with its pipeline and Casgevy starts ramping up its sales. For investors comfortable with the risk, CRISPR Therapeutics is worth considering.
A Biotech Giant: Amgen
Amgen, a biotech giant, has faced recent setbacks with its leading weight loss candidate, MariTide. However, the market’s reaction may have been overdone. MariTide demonstrated a 20% average weight loss after 52 weeks, with no weight loss plateau observed. The company’s financial results remain strong, with 23% year-over-year revenue growth to $8.5 billion in the third quarter. Amgen has several products driving top-line growth, including Tepezza and Tezspire, and a deep pipeline with plenty of potential.
As a dividend stock, Amgen offers a forward yield of 3.63%, making it an attractive option for long-term, income-seeking investors.
Investing in the Future
Before investing in CRISPR Therapeutics or Amgen, it’s essential to do your research and consider the potential risks and rewards. By taking a closer look at these two companies, you may uncover hidden gems that could provide significant returns in the years to come.
Leave a Reply